MK-8527 is a novel inhibitor of HIV-1 reverse transcriptase translocation with potential for extended-duration dosing
Fig 5
Evaluation of carbaribose modifications.
Potency, cytotoxicity, and persistence ratios in MT4-GFP cells and/or PBMCs for four compounds with carbaribose modifications. CH2, methylene; CC50, concentration of test compound required to reduce cell viability by 50%; CTG, CellTiter-Glo; GFP, green fluorescent protein; IC50, half maximal inhibitory effect; NC, not calculated (i.e., persistence ratios could not be calculated due to qualifiers in IC50A [infection performed immediately after washout] and/or IC50B [infection performed 48 h after washout]); PBMC, peripheral blood mononuclear cell.